IL-6 and soluble IL-6 receptor stimulate the production of MMPs and their inhibitors via JAK-STAT and ERK-MAPK signalling in human chondrocytes

Cell Biology International

Volumn 36, Issue 4, 2012, Pages 367-376

  Aida, Yukiko ^a   Honda, Kazuhiro ^a   Tanigawa, Shihoko ^a   Nakayama, Go ^a   Matsumura, Hideo ^a   Suzuki, Naoto ^a   Shimizu, Osamu ^a   Takeichi, Osamu ^a   Makimura, Masaharu ^a   Maeno, Masao ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Chondrocytes; Interleukin 6 (IL 6); Matrix metalloproteinase (MMP); Mitogen activated protein kinase (MAPK); Soluble IL 6 receptor (sIl 6r); Tissue inhibitors of metalloproteinase (TIMP)

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; COLLAGENASE 3; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERSTITIAL COLLAGENASE; JANUS KINASE; JANUS KINASE 3 INHIBITOR; MATRIX METALLOPROTEINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RNA; STAT PROTEIN; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE;

ARTICLE; CARTILAGE CELL; CONTROLLED STUDY; FEMUR; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CARTILAGE; CHONDROCYTES; FLAVONOIDS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; JANUS KINASE 3; MATRIX METALLOPROTEINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; SOLUBILITY; TISSUE INHIBITOR OF METALLOPROTEINASES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84859244911     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20110150     Document Type: Article

References (38)

1. Aida Y, Maeno M, Suzuki N, Shiratsuchi H, Motohashi M, Matsumura H. The effect of IL-1βb on the expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human chondrocytes. Life Sci 2005;77:3210-21.
2. Aida Y, Maeno M, Suzuki N, Namba A, Motohashi M, Matsumoto M et al. The effect of IL-1β on the expression of inflammatory cytokines and their receptors in human chondrocytes. Life Sci 2006;79:764-71.
3. Ala-aho R, Kahari VM. Collagenases in cancer. Biochimie 2005;87:273-86.
4. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro. J Biol Chem 1995;270:27489-94.
5. Bromberg JF. Activation of STAT proteins and growth control. Bioessays 2001;23:161-9.
6. Cawston T. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today 1998;4:130-7.
7. Corbel M, Boichot E, Lagente V. Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury. Braz J Med Biol Res 2000;33:749-54.
8. Dijkgraaf LC, de Bont LG, Boering G, Liem RS. Normal cartilage structure, biochemistry, and metabolism: a review of the literature. J Oral Maxillofac Surg 1995;53:924-9.
9. Dzwonek J, Rylski M, Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 2004;567:129-35.
10. Eeckhout Y, Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J 1977;166:21-31.
11. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39:237-46.
12. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107.
13. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56.
14. Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 2002;277:47366-72.
15. Huang W, Li WQ, Dehnade F, Zafarullah M. Tissue inhibitor of metalloproteinases-4 (TIMP-4) gene expression is increased in human osteoarthritic femoral head cartilage. J Cell Biochem 2002;85:295-303.
16. Ijima Y, Kobayashi M, Kubota E. Role of interleukin-1 induction of matrix metalloproteinases synthesized by rat temporomandibular joint chondrocytes and disc cells. Eur J Oral Sci 2001;109:50-9.
17. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14-23.
18. Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 2002;1592:251-63.
19. Lambert E, Dasse E, Haya B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-98.
20. Legendre F, Bogdanowicz P, Boumediene K, Pujol JP. Role of interleukin 6 (IL-6)/IL-6R-induced signal transducers and activators of transcription and mitogen-activated protein kinase/extracellular. J Rheumatol 2005;32:1307-16.
21. Malemud CJ, Islam N, Haqqi TM. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissue Organs 2003;174:34-48.
22. Martel-Pelletier J, Pelletier JP. Wanted-the collagenase responsible for the destruction of the collagen network in human cartilage. Br J Rheumatol 1996;35:818-20.
23. Martin G, Andriamanalijaona R, Grassel S, Dreier R, Mathy-Hartert M, Bogdanowicz P et al. Effect of hypoxia and reoxygenation on gene expression and response to interleukin-1 in cultured atricular chondrocytes. Arthritis Rheum 2004;50:3549-60.
24. Mohtai M, Smith RL, Schurman DJ, Tsuji Y, Torti FM, Hutchinson NI et al. Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 1993;92: 179-85.
25. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S et al. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999;107:38-44.
26. Nagamine Y, Medcalf RL, Munoz-Canoves P. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost 2005;93:661-75.
27. Namba A, Aida Y, Suzuki N, Watanabe Y, Kawato T, Motohashi M et al. Effects of IL-6 and soluble IL-6 receptor on the expression of cartilage matrix proteins in human chondrocytes. Connect Tissue Res 2007;48:263-70.
28. Okada Y, Shinmei M, Tanaka O, Naka K, Kimura A, Nakanishi I et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest 1992;66:680-90.
29. Olson MW, Gervasi DC, Mobashery S, Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem 1997;272:29975-83.
30. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:1104-17.
31. Pins GD, Collins-Pavao ME, Van De Water L, Yarmush ML, Morgan JR. Plasmin triggers rapid contraction and degradation of fibroblastpopulated collagen lattices. J Invest Dermatol 2000;114:647-53.
32. Schwab W, Schulze-Tanzil G, Mobasheri A, Dressler J, Kotzsch M, Shakibaei M. Interleukin-1beta-induced expression of the urokinase-type plasminogen activator receptor and its colocalization with MMPs in human articular chondrocytes. Histol Histopathol 2004;19:105-12.
33. Shinoda C, Takaku S. Interleukin-1 beta, interleukin-6, and tissue inhibitor of metalloproteinase-1 in the synovial fluid of the temporomandibular joint with respect to cartilage destruction. Oral Dis 2000;6:383-90.
34. Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S. Proteolyticantiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 2005;11:1251-66.
35. Smith RL. Degradative enzymes in osteoarthritis. Front Biosci 1999;4:704-12.
36. Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999;5:1569-82.
37. Taga T, Kishimoto T. Signaling mechanisms through cytokine receptors that share signal transducing receptor components. Curr Opin Immunol 1995;7:17-23.
38. Yu WH, Yu S, Meng Q, Brew K, Woessner Jr JF. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000;275:31226-32.